Johnson & Johnson $JNJ Stock Position Lowered by Werlinich Asset Management LLC

Werlinich Asset Management LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 26.2% during the third quarter, HoldingsChannel reports. The institutional investor owned 11,240 shares of the company’s stock after selling 4,000 shares during the period. Johnson & Johnson accounts for about 1.2% of Werlinich Asset Management LLC’s holdings, making the stock its 26th biggest holding. Werlinich Asset Management LLC’s holdings in Johnson & Johnson were worth $2,976,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in JNJ. Wellington Management Group LLP lifted its stake in Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock valued at $5,736,851,000 after buying an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its stake in shares of Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after acquiring an additional 1,225,676 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Johnson & Johnson by 8.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock worth $3,575,255,000 after purchasing an additional 1,376,828 shares in the last quarter. Amundi raised its stake in Johnson & Johnson by 17.5% in the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after purchasing an additional 2,001,139 shares during the last quarter. Finally, Nuveen LLC boosted its stake in Johnson & Johnson by 6.9% during the 4th quarter. Nuveen LLC now owns 10,609,171 shares of the company’s stock worth $2,195,568,000 after purchasing an additional 683,967 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra), its targeted oral IL-23 receptor peptide for moderate-to-severe plaque psoriasis. Nearly three-quarters of adults and adolescents achieved clear or almost clear skin at two years, with responses sustained and a favorable safety profile. The results strengthen the potential of ICOTYDE as a future growth product and were presented at a dermatology meeting. Johnson & Johnson ICOTYDE two-year psoriasis data
• Positive Sentiment: Guggenheim reaffirmed a Buy rating, while Morgan Stanley also issued a Buy rating. The positive analyst view reflects JNJ’s diversified healthcare portfolio, drug launches and defensive dividend appeal. Guggenheim reaffirms Buy rating
• Positive Sentiment: Several investment commentaries continue to present JNJ as a dividend-focused healthcare holding, emphasizing its long record of dividend growth and relatively dependable cash generation compared with higher-yielding but riskier peers. Healthcare Dividend Aristocrats
• Neutral Sentiment: JNJ is approaching its third-quarter earnings report with expectations for continued strength in pharmaceuticals and newer product launches. Investors will focus on revenue growth, guidance and the pace of Stelara-related sales erosion.
• Negative Sentiment: Analysts warn that biosimilar competition for Stelara and challenges in the MedTech business could weigh on near-term growth, limiting the impact of otherwise strong drug performance. J&J stock ahead of Q3 earnings
• Negative Sentiment: Upcoming patent expirations for Imbruvica and Darzalex create a longer-term “patent cliff” risk, potentially pressuring pharmaceutical revenue unless pipeline products and acquisitions offset lost exclusivity. J&J patent cliff analysis
• Negative Sentiment: Boston Scientific has sued JNJ subsidiary Atraverse over alleged patent infringement involving the Hotwire cardiology device, seeking damages and an injunction. The financial impact is uncertain but adds legal and competitive risk to the MedTech segment. Boston patent lawsuit against J&J subsidiary

Johnson & Johnson Stock Up 1.9%

Johnson & Johnson stock opened at $261.27 on Friday. The company has a market capitalization of $629.64 billion, a PE ratio of 30.27, a price-to-earnings-growth ratio of 2.60 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. Johnson & Johnson has a fifty-two week low of $184.66 and a fifty-two week high of $281.07. The firm has a 50 day moving average price of $265.83 and a 200 day moving average price of $249.01.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%. The company had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. During the same period in the prior year, the firm earned $2.77 earnings per share. The firm’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Research analysts expect that Johnson & Johnson will post 11.18 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a dividend of $1.34 per share. The ex-dividend date was Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is 62.11%.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. Royal Bank Of Canada boosted their price target on shares of Johnson & Johnson from $287.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday. Morgan Stanley increased their price target on Johnson & Johnson from $284.00 to $294.00 and gave the company an “overweight” rating in a report on Thursday, July 16th. Guggenheim restated a “buy” rating and issued a $287.00 target price on shares of Johnson & Johnson in a report on Wednesday. UBS Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, September 22nd. Finally, Weiss Ratings raised shares of Johnson & Johnson from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $276.22.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 87,569 shares of company stock worth $23,064,544 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.